Author:
Schwartz Jason J.,Lee Edward,Butler Ashley P.,Facklam David P.,Franks Billy,Spalding James R.,Vassilakis Maria E.,Thal Gary D.,Irish William D.
Funder
Astellas Pharma Global Development
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference13 articles.
1. Peters DH, Fitton A, Plosker GL, Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs. 1933;46(4):746–94.
2. Molnar AO, Fergusson D, Tsampalieros AK, et al. Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis. BMJ. 2015;350:h3163.
3. Rodrigo E, San D, Ruiz J, et al. High intra-patient variability in tacrolimus trough blood levels increases the risk of death-censored graft loss after kidney transplantation (abstract). Am J Transplant. 2015;15(Suppl 3).
https://atcmeetingabstracts.com/abstract/high-intra-patient-variability-in-tacrolimus-trough-blood-levels-increases-the-risk-of-death-censored-graft-loss-after-kidney-transplantation/.
4. Klintmalm GB. Immunosuppression, generic drugs and the FDA. Am J Transplant. 2011;11(9):1765–6.
5. Trofe-Clark J, Gabardi S, McDevitt-Potter L, Alloway RR. Immunosuppression, generic drugs and the FDA. Am J Transplant. 2012;12(3):792–3.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献